ExozymesEXOZ
13F holders, Q2 2026 (June 30)9holders +2
2new positions
0sold out
$8.43avg. 13F price*
At the end of Q2 2026, 9 institutions reported holding Exozymes Inc. (EXOZ) in their 13F filings, up 2 from Q1 2026. 2 opened new positions and 0 sold out. The largest holders were Vanguard Capital Management LLC ($464K), Davidson Kahn Capital Management, LLC ($211K) and Geode Capital Management, LLC ($197K).
- Company
- Exozymes Inc.
- CUSIP
- 461874109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $211K |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 62,377 shares bought and 968 shares sold, net +61,409 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Vanguard Capital Management LLC | 0.00% | Add +147.8% | 54,985 | $464K |
| Davidson Kahn Capital Management, LLC | 0.09% | New | 25,000 | $211K |
| Geode Capital Management, LLC | 0.00% | Add +6.9% | 23,406 | $197K |
| BlackRock, Inc. | 0.00% | Add +41.4% | 9,610 | $81K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 9,426 | $79K |
| Morgan Stanley | 0.00% | No change | 1,250 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -73.5% | 349 | $3K |
| UBS Group AG | 0.00% | Add +745.8% | 203 | $2K |
| Barclays PLC | 0.00% | New | 75 | $632 |
"% of holder's portfolio" is EXOZ's weight in each manager's 13F, not the share of Exozymes Inc. the manager owns.